Fusion Pharmaceuticals To Acquire Ph 2 Program For 225Ac-PSMA I&T, A Radiopharmaceutical Targeting metastatic CRPC February 22, 2023
Updated Data Demonstrating Improved Outcomes from Niraparib + Abiraterone + Prednisone in 1L BRCA+ve metastatic CRPC announced February 22, 2023
Positive TALZENNA® and XTANDI® Combination Data from Ph 3 TALAPRO-2 Study Announced February 22, 2023
Final Results of Key Secondary OS Endpoint From Phase 3 PROpel Trial presented, OS endpoint not met February 22, 2023
KEYNOTE-991 Trial Evaluating KEYTRUDA® Plus Enzalutamide and Androgen Deprivation Therapy in Patients With mHSPC to Stop for Futility February 1, 2023
Enrollment in Ph 1 Trial of ADXS-504 for the Treatment of Early Prostate cancer completed January 17, 2023
Positive Top-line Results from Pivotal Ph 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate Cancer Announced January 11, 2023
Lynparza + abiraterone approved in the EU in 1L metastatic CRPC based on Ph 3 PROpel trial results January 4, 2023
PDUFA date extended by three months to review Lynparza + abiraterone & prednisone supplemental NDA for metastatic CRPC December 19, 2022
European Commission Approves Pluvicto® For Treatment Of Progressive PSMA+ve metastatic CRPC December 19, 2022
Pluvicto™ shows statistically significant & clinically meaningful rPFS benefit in patients with PSMA+ve metastatic CRPC December 12, 2022
Lantheus and POINT Biopharma Announce Strategic Collaboration and Exclusive License Agreements for the Commercialization of PNT2002 & PNT2003 November 23, 2022
Lynparza – abiraterone combo recommended for approval in the EU by CHMP in 1L metastatic CRPC November 23, 2022
First Patient Successfully Dosed in Ph 1 Study of Pindnarulex in Combination with Talazoparib for the Treatment of Prostate Cancer November 16, 2022
Enrollment into Ph 1 study of EPI-7386 with apalutamide/abiraterone acetate plus prednisone in metastatic CRPC patients suspended due to operational recruitment challenges November 16, 2022
TRITON3 Ph 3 Trial Of Rubraca Achieves Primary Endpoint In Men With metastatic CRPC With BRCA Or ATM Mutations October 12, 2022
Ph 3 TALAPRO-2 study of TALZENNA® + XTANDI® in metastatic CRPC patients met primary endpoint of rPFS vs placebo plus XTANDI October 12, 2022
